← Leaderboards
Carl G Maki
Harvard University (Medical School)
$8,075,653
Attributed
$8,075,653
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $522.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,075,653 · 8
By mechanism
R01$6,916,551 · 5
R21$1,159,102 · 3
Top collaborators
No co-investigators on record.
Most similar at Harvard University (Medical School)
Same institution · by research overlap
- Sam W Lee$15,278,254
- Karl Munger$19,605,537
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMalignant NeoplasmsGrantBaseResistanceDna DamageIn VivoTumorResponsePathway InteractionsProteinsCell LineTumor XenograftPublic Health RelevanceTumor Suppressor ProteinsSignal TransductionPreventCollectionOverexpressionTissuesTp53 GeneKnock-DownRecurrenceFamily
Grant awards (32)
Synthetic lethal targeting of KRAS/KEAP1 co-mutant non-small cell lung cancer$340,215
R01 · FY2025 · CA · contact PI
Synthetic lethal targeting of KRAS/KEAP1 co-mutant non-small cell lung cancer$340,215
R01 · FY2024 · CA · contact PI
A synthetic lethal approach for targeting p53 deficient triple negative breast cancer$175,429
R21 · FY2024 · CA · contact PI
A synthetic lethal approach for targeting p53 deficient triple negative breast cancer$221,595
R21 · FY2023 · CA · contact PI
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer$354,563
R01 · FY2020 · CA · contact PI
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer$343,925
R01 · FY2019 · CA · contact PI
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer$354,563
R01 · FY2018 · CA · contact PI
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer$12,858
R01 · FY2018 · CA · contact PI
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer$354,563
R01 · FY2017 · CA · contact PI
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer$56,855
R01 · FY2017 · CA · contact PI
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer$354,563
R01 · FY2016 · CA · contact PI
Identification and Targeting Therapy Resistant Osteosarcoma$167,987
R21 · FY2016 · CA · contact PI
Identification and Targeting Therapy Resistant Osteosarcoma$215,244
R21 · FY2015 · CA · contact PI
Modeling The Etiology of P53 Mutated Cancer Cells$163,650
R21 · FY2014 · CA · contact PI
Cellular Responses to p53 Activation by Nutlin-3a$283,799
R01 · FY2013 · CA · contact PI
Modeling The Etiology of P53 Mutated Cancer Cells$215,197
R21 · FY2013 · CA · contact PI
Cellular Responses to p53 Activation by Nutlin-3a$301,913
R01 · FY2012 · CA · contact PI
Cellular Responses to p53 Activation by Nutlin-3a$301,913
R01 · FY2011 · CA · contact PI
Cellular Responses to p53 Activation by Nutlin-3a$311,250
R01 · FY2010 · CA · contact PI
Cellular Responses to p53 Activation by Nutlin-3a$311,250
R01 · FY2009 · CA · contact PI
Physical and Functional Interactions Between PML & MDM2$227,742
R01 · FY2008 · CA · contact PI
Physical and Functional Interactions Between PML & MDM2$227,742
R01 · FY2007 · CA · contact PI
p53 localization in normal and human tumor cells$247,573
R01 · FY2006 · CA · contact PI
Physical and Functional Interactions Between PML & MDM2$234,544
R01 · FY2006 · CA · contact PI
p53 localization in normal and human tumor cells$253,531
R01 · FY2005 · CA
Physical and Functional Interactions Between PML &MDM2$240,188
R01 · FY2005 · CA
p53 localization in normal and human tumor cells$248,544
R01 · FY2004 · CA
Physical and Functional Interactions Between PML &MDM2$240,188
R01 · FY2004 · CA
UBIQUITINATION AND STABILITY OF P53 AND P73$243,413
R01 · FY2003 · CA
UBIQUITINATION AND STABILITY OF P53 AND P73$251,045
R01 · FY2002 · CA
UBIQUITINATION AND STABILITY OF P53 AND P73$243,731
R01 · FY2001 · CA
UBIQUITINATION AND STABILITY OF P53 AND P73$235,865
R01 · FY2000 · CA